$SLNO
SOLENO THERAPEUTICS INC

2022 Q1 Form 10-Q Financial Statement

#000156459022019266 Filed on May 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.643M $2.980M
YoY Change -11.31% 49.0%
% of Gross Profit
Research & Development $3.988M $7.164M
YoY Change -44.33% 7.01%
% of Gross Profit
Depreciation & Amortization $492.0K $490.0K
YoY Change 0.41% 0.0%
% of Gross Profit
Operating Expenses $5.773M $9.156M
YoY Change -36.95% -1.36%
Operating Profit -$5.773M -$9.156M
YoY Change -36.95% -1.36%
Interest Expense $22.00K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $49.00K $202.0K
YoY Change -75.74% -94.1%
Pretax Income -$5.724M -$8.950M
YoY Change -36.04% 52.73%
Income Tax
% Of Pretax Income
Net Earnings -$5.724M -$8.954M
YoY Change -36.07% 52.85%
Net Earnings / Revenue
Basic Earnings Per Share -$1.07
Diluted Earnings Per Share -$71.53K -$112.3K
COMMON SHARES
Basic Shares Outstanding 5.335M
Diluted Shares Outstanding 5.335M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.97M $41.61M
YoY Change -30.37% 176.11%
Cash & Equivalents $29.00M $41.61M
Short-Term Investments
Other Short-Term Assets $1.004M $920.0K
YoY Change 9.13% 61.4%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $29.98M $42.53M
YoY Change -29.51% 171.93%
LONG-TERM ASSETS
Property, Plant & Equipment $377.0K $80.00K
YoY Change 371.25% -78.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $40.00K
YoY Change
Total Long-Term Assets $12.57M $14.18M
YoY Change -11.37% -13.9%
TOTAL ASSETS
Total Short-Term Assets $29.98M $42.53M
Total Long-Term Assets $12.57M $14.18M
Total Assets $42.55M $56.71M
YoY Change -24.98% 76.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.411M $4.670M
YoY Change -48.37% 34.2%
Accrued Expenses $4.463M $4.610M
YoY Change -3.19% 31.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.313M $9.510M
YoY Change -23.1% 30.45%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $8.772M $9.630M
YoY Change -8.91% 15950.0%
Total Long-Term Liabilities $8.772M $9.630M
YoY Change -8.91% 15950.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.313M $9.510M
Total Long-Term Liabilities $8.772M $9.630M
Total Liabilities $16.09M $19.14M
YoY Change -15.96% -15.42%
SHAREHOLDERS EQUITY
Retained Earnings -$219.1M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $26.46M $37.57M
YoY Change
Total Liabilities & Shareholders Equity $42.55M $56.71M
YoY Change -24.97% 76.6%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$5.724M -$8.954M
YoY Change -36.07% 52.85%
Depreciation, Depletion And Amortization $492.0K $490.0K
YoY Change 0.41% 0.0%
Cash From Operating Activities -$6.400M -$7.488M
YoY Change -14.53% 32.32%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $4.000K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$4.000K
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 14.03M -125.0K
YoY Change -11325.6% 3025.0%
NET CHANGE
Cash From Operating Activities -6.400M -7.488M
Cash From Investing Activities 0.000 -4.000K
Cash From Financing Activities 14.03M -125.0K
Net Change In Cash 7.670M -7.617M
YoY Change -200.7% 34.5%
FREE CASH FLOW
Cash From Operating Activities -$6.400M -$7.488M
Capital Expenditures $0.00 $4.000K
Free Cash Flow -$6.400M -$7.492M
YoY Change -14.58% 32.39%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 slno Asset Acquisition Contingent Consideration Change In Fair Value
AssetAcquisitionContingentConsiderationChangeInFairValue
-858000
CY2021Q1 slno Asset Acquisition Contingent Consideration Change In Fair Value
AssetAcquisitionContingentConsiderationChangeInFairValue
-987000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
5773000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
9156000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5773000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9156000
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-27000
CY2021Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-201000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
22000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
49000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
202000
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-8954000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5726000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8954000
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
120088816
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
40000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
175000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6362000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Income Tax Deficiency From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation
16000
CY2022Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1034000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7488000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13766000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
45547000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1095000
CY2022Q1 slno Proceeds From Sale Of Common Stock And Pre Funded Warrants Net Of Costs
ProceedsFromSaleOfCommonStockAndPreFundedWarrantsNetOfCosts
14048000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Income Tax Deficiency From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation
120000
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
16000
CY2021Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
120000
CY2021Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
5000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-8954000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
37568000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14032000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-125000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7670000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-5724000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-8954000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7617000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21304000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
26461000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42546000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49224000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
120088816
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
80000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28974000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
231068000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-213355000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
27000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
423000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6400000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41607000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
492000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
489000
CY2022Q1 slno Noncash Lease Expense
NoncashLeaseExpense
71000
CY2021Q1 slno Noncash Lease Expense
NoncashLeaseExpense
76000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
644000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1095000
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-27000
CY2021Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-201000
CY2022Q1 slno Asset Acquisition Contingent Consideration Change In Fair Value
AssetAcquisitionContingentConsiderationChangeInFairValue
-858000
CY2021Q1 slno Asset Acquisition Contingent Consideration Change In Fair Value
AssetAcquisitionContingentConsiderationChangeInFairValue
-987000
CY2022Q1 slno Other Non Cash Reconciling Items
OtherNonCashReconcilingItems
-2000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-114000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-98000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1046000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1180000
CY2022Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-130000
CY2021Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-594000
CY2022Q1 slno Increase Decrease In Accrued Clinical Trial Site Costs
IncreaseDecreaseInAccruedClinicalTrialSiteCosts
101000
CY2021Q1 slno Increase Decrease In Accrued Clinical Trial Site Costs
IncreaseDecreaseInAccruedClinicalTrialSiteCosts
351000
CY2022Q1 slno Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-34000
CY2021Q1 slno Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-82000
CY2022Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
37000
CY2021Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
41000
CY2022Q1 slno Unpaid Costs For Issuing Common Stock And Pre Funded Warrants
UnpaidCostsForIssuingCommonStockAndPreFundedWarrants
282000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5700000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-219100000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29000000.0
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the financial statements and accompanying notes. Actual results could differ from those estimates. Key estimates included in the financial statements include the valuation of deferred income tax assets, the valuation of financial instruments, stock-based compensation, accrued costs for services rendered in connection with third-party contractor clinical trial activities, and the valuation of contingent liabilities for the purchase price of assets obtained through acquisition.</span></p>
CY2021 slno Percentage Of Probability Of Achieving Milestones
PercentageOfProbabilityOfAchievingMilestones
0.72
CY2022Q1 slno Percentage Of Probability Of Achieving Milestones
PercentageOfProbabilityOfAchievingMilestones
0.72
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
600000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
300000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
300000
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.09
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P14M
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
291000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
159000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
450000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
81000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
76000
CY2021Q1 us-gaap Variable Lease Cost
VariableLeaseCost
3000
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
5000
CY2021Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
7000
CY2022Q1 slno Operating Lease Cost And Sublease Income
OperatingLeaseCostAndSubleaseIncome
86000
CY2021Q1 slno Operating Lease Cost And Sublease Income
OperatingLeaseCostAndSubleaseIncome
86000
CY2021Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
2000
CY2021Q1 slno Finance Lease Cost
FinanceLeaseCost
2000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
644000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1095000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.017
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.88
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.25
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.79
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
88667361
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7074176

Files In Submission

Name View Source Status
0001564590-22-019266-index-headers.html Edgar Link pending
0001564590-22-019266-index.html Edgar Link pending
0001564590-22-019266.txt Edgar Link pending
0001564590-22-019266-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
slno-10q_20220331.htm Edgar Link pending
slno-10q_20220331_htm.xml Edgar Link completed
slno-20220331.xsd Edgar Link pending
slno-20220331_cal.xml Edgar Link unprocessable
slno-20220331_def.xml Edgar Link unprocessable
slno-20220331_lab.xml Edgar Link unprocessable
slno-20220331_pre.xml Edgar Link unprocessable
slno-ex311_6.htm Edgar Link pending
slno-ex312_8.htm Edgar Link pending
slno-ex321_9.htm Edgar Link pending
slno-ex322_7.htm Edgar Link pending